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Introduction
‘Nano’ is derived the Greek word for ‘dwarf’ and is used to 
describe structures and objects that are sized within the scale of 1 to 
100 nanometres (x10-9 m) [1]. Nanotechnology can be defined as the 
application of structures of this size [1]. It is rapidly becoming a reality 
that nanotechnology allows the creation of new materials for a wide 
array of purposes ranging from medical, electronic, biomaterials, to 
even energy production.
The medical applications of nanotechnology are referred to as 
Nanomedicine. This is a wide and exciting field with almost boundless 
possibilities, with the possibility for nanotechnology being used for 
applications ranging from the use of nanomaterials, nanoelectronic 
biosensors and has a wide range of future applications of molecular 
nanotechnology that could be explored. One of these applications is 
the use of targeted nanocarriers to transport drugs to the target site of 
the disease where they can be released. There are many problems that 
need to be overcome, but this is an area that shows enormous potential. 
This review focuses on diseases that reside in the central nervous 
system (CNS), in particular the brain, and how nanocarriers can be 
designed and used to treat and diagnose them. This will be with 
particular reference to cancerous tumours. Currently the method 
for treating and diagnosing diseases in the brain is to use free 
drugs or radiolabelled molecules to get to the target site and fulfil 
its function. The imaging and therapy with small molecules have 
many disadvantages that could be addressed via encapsulation, or 
attachment, methods in order to increase their performance, including 
not being prematurely interacting with the biological environment or 
being prematurely removed from the body. Therapy and imaging with 
small molecules also suffer from issues of entering the target site, as the 
brain is extremely well protected from toxic molecules including drugs 
and imaging drugs. For this reason nanocarriers of correct physico-
chemical characteristics are currently being strongly considered to 
address these issues. This review will explore the problems associated 
with drug delivery into the brain and will explain the possible avenues 
that could be explored to resolve them, and review their potential for 
using nanodimensional objects for the brain targeting.
One exciting prospect that has recently emerged is the idea of 
Nanotheranostics, which is emerging from the synergy of the two areas 
mentioned: diagnostics and therapy using nanodimensional objects. 
The vision for Nanotheranostics is that nanocarriers can be designed 
that will serve a dual purpose, allowing both treatment and diagnosis 
to be contained in an ‘all-in-one’ package. The nanocarriers will be 
designed to target a certain disease. These nanocarriers will also have a 
probe inserted into their design to allow them to be tracked in the body. 
Therefore if the nanocarriers accumulate in one place, i.e. the target 
site of the disease, then this will allow doctors to further investigate 
this area to confirm that the nanocarriers are reacting to diseased cells. 
These nanocarriers will also carry a drug that will be released if the 
nanocarrier binds to the cell, starting the therapy of the disease making 
the treatment of the diagnosis immediate and saving valuable time.
This field is still in its infancy, and although it has many applications 
only a few are currently being explored. The most exciting area is the 
investigation into the use of these nanocarriers for the diagnosis and 
treatment of cancerous tumours in the brain [2]. 
The two different ways of targeting nanocarriers are via processes 
called active targeting or passive targeting. These utilise different 
systems to gain access to the tumorous cells, but unfortunately the 
precise design requirements for achieving successful active or passive 
transport into cancerous tumours in the brain has not been discovered. 
These targeting methods have been successfully used for other tumours 
site. 
A passive targeting nanocarrier does not have any additions to its 
structure to direct it to the desired diseased target site; it instead relies 
on its properties (charge, size) to arrive at the correct location in the 
body. An active targeting nanocarrier, on the other hand, does possess 
ligands attached onto its structure that guide it to the correct location, 
and should act like a key to let it gain access to the target cell. This is 
represented in Figure 1. The idea of active targeting is still an idea in 
early development and still has many issues to overcome. 
Passive targeting works through faults that develop in the blood 
*Corresponding author: Sofia I Pascu ,Chemistry Department, University 
of Bath, Claverton Down, Bath, UK, E-mail: s.pascu@bath.ac.uk
Received February 09, 2012; Accepted March 08, 2012; Published March 11, 
2012
Citation: Chapman M, Pascu SI (2012) Nanomedicines Design: Approaches 
towards the Imaging and Therapy of Brain Tumours. J Nanomedic Nanotechnol 
S4:006. doi:10.4172/2157-7439.S4-006
Copyright: © 2012 Chapman M, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Nanomedicines Design: Approaches towards the Imaging and Therapy of 
Brain Tumours  
Matthew Chapman and Sofia I. Pascu*
Chemistry Department, University of Bath, Claverton Down, Bath, UK
Abstract
Nanotechnology has potential to revolutionize diagnosis and therapy of diseases in the central nervous system 
through nanotheranostics. This simply states that a nanocarrier can be designed in an ‘all-in-one’ approach to facilitate 
both the functions of a diagnostic and a therapeutic drug. There are many challenges that must be overcome for 
these nanocarriers to become a successful design, but if resolved nanocarriers could pave the way for personalised 
medicine. This review highlights several new ideas behind nanotheranostics design and testing with a particular focus 
on cancerous tumours in the brain.
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vessels that surround a diseased site, an example of this is in tumorous 
cells. Tumours require a blood supply to survive, and use angiogenesis 
to create new blood vessels from existing ones. The majority of tumours 
develop leaky blood vessels and shown poor lymphatic drainage due to 
rapid and defective angiogenesis [2]. Free drugs diffuse non-specifically 
into these cells but correctly designed nanocarriers escape into the 
tumour cells through leaky blood vessels via the enhanced permeability 
and retention effect [3]. This effect only affects molecules of a certain 
size (200 - 400nm) and these molecules as a result tend to accumulate in 
tumour cells [4-6]. In this example, nanocarriers [3] are then retained 
by the dysfunctional lymphatic drainage in tumours which allows the 
drugs to be released near the tumour site. 
Passive targeting suffers from several limitations. Due to the 
random nature of the process the nanocarriers may accumulate in one 
section of the tumour preventing the drugs to diffuse equally across the 
tumour [2]. This is a lack on of control with this method means that the 
nanocarriers often induce the function efflux proteins, which remove 
the nanocarrier from the cell [7,8] This effect will be investigated in 
detail in the process of this review. Passive targeting is further limited as 
tumours don’t show the same permeability throughout their structure, 
therefore the enhanced permeability and retention effect becomes less 
effective [9].
Active targeting nanocarriers would solve these problems and 
could provide a general solution for drug delivery to the CNS, 
including tumorous cells in the brain. The design of these actively 
targeted nanocarriers that target drugs to the diseased site, without 
affecting healthy tissues, whilst avoiding side effects is currently a 
matter of intense research as there are still many problems that must 
be overcome.
Problem
Many challenges related to the drug design and drug delivery route 
must be resolved before actively targeted nanocarriers can be a viable 
route for drugs to the brain to diagnose or cure diseases of the CNS 
including tumours in the brain in a selective way. This is currently an 
area of intense research.
Some of these same problems have already been solved by simple 
chemicals which target brain (e.g. glucose, morphine) and are recently 
being extended to nanomaterials, but one problem called the blood 
brain barrier (BBB) is the main bottleneck to the design for achieving 
successful active or passive transport. A key issue related to drug design 
is that drugs and nanocarriers must have a long circulation time in 
blood to allow the active targeting to take place. The biocompatibility 
of the drug and the ability to bypass the liver are the most important 
factors that correlate to circulation time [10]. Biocompatibility allows 
the drugs and nanocarriers to avoid being detected as a foreign body 
and destroyed by body’s natural defences, i.e. phagocytosis. The ability 
to bypass the liver prevents the drug or nanocarrier to be removed 
from the body before it is able mission is complete. These attributes 
can be given to nanocarriers by correct design and will be discussed 
in the ‘Probe Design toward a Targeted Delivery Solution’ section of 
this review. The solution to crossing BBB and the reasons behind the 
current issues for CNS drugs are explored below.
Blood brain barrier (BBB)
The function of the BBB is to protect the CNS from toxic molecules 
that, for example, may be ingested in food.11 In addition to of this 
function the BBB serves as a barrier to drugs for treatment of diseases of 
the CNS. This means that only a very small selection of drugs, of correct 
liphophylicity and with small molecular weights manage to enter the 
CNS through the BBB. No drugs with large molecular weights enter the 
CNS through the BBB, except for a small minority of natural proteins, 
e.g. insulin, that have specific pathways designed to carry them across 
the BBB. The current challenge is to devise new nanodimensional 
targeting drugs having the ability to cross BBB. 
The structure of the Blood Brain Barrier involves endothelial cells 
that form the walls of the capillaries in the brain. These endothelial 
cells are surrounded by tight junctions and lack the large pores that are 
generally found in capillary walls (Figure 2). Tight junctions are formed 
by two closely associated cells, there membranes join together to form 
a virtually impermeable barrier to most substances. Tight junctions 
prevent many polar solutes from entering the CNS [11]. Lipid soluble 
molecules can cross the BBB through the endothelial cells, but this is 
regulated by ATP requiring efflux transporters that selectively remove 
Active Targeting Nanocarrier
Passive Targeting Nanocarrier
Drug or Imaging agent
Figure 1: Schematic representation of active and passive targeting. The li-
gands attached to the active targeting molecule (red) to guide it to the target 
site, represented by the ‘key’. The diagram also reveals the two methods for 
storing drug molecules and imaging agents, either encapsulated within the 
nano-carrier or covalently linked to the external nano-structure.
Figure 2: A schematic representation of a cell and its nucleus: Diagram shows 
of endocyotic event caused by a ligand on a nanocarrier binding to a receptor 
on the surface of the cell. The resulting cluster, along with the macromolecule, 
‘pinches off’ into a vesicle which is then engulfed into the cell, moved across 
and exocytosed on the opposite plasma membrane.
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molecules from the cell. This ensures that only selected molecules 
with specific physical and thus reactivity pathways can cross the BBB. 
The transport across the Blood Brain Barrier is a matter of intensive 
research. The brain is the most energy consuming organ of the body 
and has developed systems to transport the wide variety of required 
substances across the BBB. The use of these systems will be key to 
the success of using nanocarriers for active targeting of drugs to cure 
diseases of the CNS. 
Passive diffusion: A wide range of small lipid soluble substances can 
passively diffuse through the cell membrane and cross the endothelium 
[12]. It is through this pathway that most current CNS drugs cross 
the BBB. These drugs must possess a number of physicochemical 
properties. This has been a major area of research as it is hoped that 
once the properties required are defined more successful CNS drugs 
can be designed. It has been shown that molecules of a molecular weight 
greater than 450 Daltons will not be able to cross the BBB using this 
pathway [13]. This makes the design of effective CNS drugs extremely 
difficult. Lipid solubility is another important physicochemical factor. 
It has been shown that the more lipid soluble a drug, the greater the 
probability it will cross the BBB. This has been experimentally shown 
to be determined by the logD octanol/buffer partition coefficient at pH 
7.4 [14].
In addition, there is a wide range of other factors that also restrict 
the BBB permeability. These are not an absolute indication of BBB 
permeability as CNS drugs have been designed that do not possess 
these properties. Therefore, a defined set of rules for BBB permeability 
may not be the best way forward for the design of new drugs capable of 
targeting the CNS. A key issue is that efflux transporters prevent many 
CNS drugs from entering the BBB via passive diffusion.
ABC transporter efflux: These transporters are ATP-dependant 
membrane glycoproteins that actively remove molecules as they diffuse 
through the membrane or from the cytoplasm. The design of the drug to 
maximise its BBB penetration, by increasing the lipid solubility, is often 
counter-productive as this increase can lead to an increased likelihood 
of becoming effluxed by one of these transporters [15-19]. The most 
important of these are P-glycoprotein (Pgp), the Multidrug Resistance-
associated Proteins (MRP 1-5*) and Breast Cancer Resistance Protein 
(BCRP) [16,20,21].
In addition to designing compounds that have the physicochemical 
properties needed to enable passive diffusion across the BBB, it is now 
required that these compounds are poor substrates for these efflux 
transporters. This fact adds to the increasing difficulty in designing 
a successful CNS drug. Considering that using this method only a 
relatively small proportion of the drug that is administered crosses the 
BBB other methods must be considered. This is the main reason why 
actively targeted nanocarriers could hold the answer, as many drug-
like, active molecules can be delivered to target in an ‘all-in one’ design 
whilst keeping the actual dose of the overall carrier extremely small.
Carrier mediated influx via solute carriers: Carrier mediated 
influx via solute carriers may offer the possibility of drugs crossing 
the BBB via active transport. Water-soluble carriers transport vital 
metabolites such as glucose, other sugars, lactate, nucleosides, fatty 
acids and vitamins into the brain [11].
These solute carriers may be:
•	 Bidirectional:	 determined	 by	 the	 substrate	 concentration	
gradient
•	 Unidirectional: either into or out of the cell depending on the 
substrate
•	 Or,	involving	an	exchange	of	one	substrate	for	another,	often	
driven by an ion gradient [11].
In order to utilize this pathway, drugs must be designed to closely 
resemble these nutrients. This can be closely linked to the idea of the 
Trojan horse in Greek mythology: the method involves ‘tricking’ the 
solute carriers into thinking the drug is another molecule. 
This method would increase the administered dose of the drug that 
enters the CNS as the drug is now actively transported across the BBB. 
However, this puts even tighter restrictions on the already complex 
drug design but opens up interesting avenues for synthetic chemists 
and pharmacologists.
Transcytosis (Receptor mediated and adsorptive mediated): 
Transcytosis transports macromolecules across the BBB and into the 
CNS. The majority of large molecules are prevented from entering the 
CNS but this specific pathway has developed to allow the transport of 
necessary large molecules and complexes [11].
This pathway is the best candidate for allowing nanocarriers to 
cross the BBB as it is the only pathway that allows for the relatively 
large molecular weights of nanocarriers.
In Receptor Mediated Transcytosis (RMT) specific receptors on 
the surface of the endothelial cell bind to specific ligands attached to 
macromolecules. This triggers an endocyotic event where the receptor 
and ligand bind forming a cluster. The resulting cluster, along with the 
macromolecule, ‘pinches off’ into a vesicle (Figure 2) [11]. This vesicle 
is then engulfed into the cell, moved across and exocytosed on the 
opposite plasma membrane [11]. In Adsorptive Mediated Transcytosis 
(AMT) there must be an excessive positive charge on the molecule [22]. 
When this interacts with the cell surface binding sites, a similar process 
occurs. 
RMT is the most suited pathway for larger drugs such as those 
supported on nanocarriers to be delivered to cells as it could allow 
nanocarriers to cross the BBB if a specific ligand is found and attached 
to the outside of the probe (Figure 3).
Problems may arise if the ligand is not specific to the BBB as is 
recognised by receptors elsewhere as the nanocarrier could be taken up 
into other cells in the body causing side effects. Ideally the ligand used 
Nanocarrier
Receptor
on target
cell, i.e.
tumour cell
Targeting
group
Figure 3: T Schematic representation of a nanocarrier incorporating an imag-
ing or therapeutic molecule ‘M’ with an attached ligand. If the correct ligand 
is added and it comes in contact with the correct ligand, as shown then an 
endocyotic event will be triggered.
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should correspond to a receptor that is over-expressed at the target area 
to improve active targeting. This has been an area of much research 
and Table 1 shows a list of ligands and associated receptors that could 
be used for tumorous cells. The advantage of using this pathway is the 
flexibility that it offers as there is not several physicochemical properties 
that the nanocarrier is required to process. AMT is not as suitable as it 
lacks the specificity required for nanocarriers.
Leukocytes: Leukocytes cross the BBB via leukocyte extravasation 
through endothelial cells either close to the tight junctions or via 
modified tight junctions [11]. This pathway may have the potential to 
have a great impact on drugs’ ability to cross the BBB, but currently not 
enough is known in this area to take advantage of this pathway in the 
drug design. Current research involves opening the tight junctions: this 
could be potentially dangerous as then anything can enter the brain, 
even harmful substances. If further research is done in this area this 
pathway could hold the answer, but there will always be an inherent 
risk in altering the tight junctions of the BBB. 
The examination of the pathways through which molecules 
can cross the BBB has revealed the reasons why current CNS drugs 
struggle to cross the BBB. It has also shown that the receptor mediated 
transcytosis (RMT) is the most suitable pathway for nanocarriers to 
cross. More research must be completed in this area to find the correct 
receptors to use, but this area does show great potential. 
Probe Designed Towards a Targeted Delivery Solution
To design a probe to take advantage of the RMT pathway to deliver 
drugs to the site of a cancerous tumour, there are multiple factors that 
must be taken in to account. We must consider the material used to act 
as the nanocarrier, the properties of that can be given to that material 
and how the drug molecule will be attached. 
Choice of nanocarriers: selected nanomaterials for drug 
delivery
There is a vast amount of research in the field of materials chemistry 
proposing new materials that are all currently under development for 
biomedical applications. The only feature in common all these materials 
have is there high surface to volume ratio, which allows a high density 
of ligands to be attached. This allows medical chemist to alter the 
material’s properties for the specific function on the nanocarrier. This 
review will only focus on a few that fit the desired properties for active 
targeting. In Figure 4 the materials that are discussed in this review are 
circled in green.
Polymers: Polymeric nanoparticles were the first polymeric 
nanocarrier studied for drug delivery devices; they were prepared from 
a block of polymeric material giving the material an increased blood 
circulation time and a reduced phagocytic uptake [10]. Biodegradable 
polymers were then incorporated to maximise the tissue compatibility 
and minimise the toxicity of the material [25]. This basic idea of 
incorporating biodegradable polymers into the stable material to alter 
its properties is one of the basic fundamental ideas behind deign of a 
targeted delivery solution. It has been shown that addition of materials 
such as poly(ethylene glycol) (PEG) and other bioactive peptides have 
been proven to minimise uptake in liver cells and result in greater 
bioavailability [10]. This is a perfect example of the use of this simple 
technique is how it is possible to increase nanocarriers properties 
through simple addition of ligands.
Polymer based nanoparticles have since been developed into a more 
complicated field with a wide and successful range of nanocarriers to 
include bionanocapusles and solid lipid nanoparticles. Polymeric 
nanocarriers internalise the drugs giving the material excellent control 
over the degradation and release of that drug through the properties of 
the polymer used.
Vesicles: Liposomes are the simplest forms of vesicles and are the 
most prevalent in this area; in particular for passive targeting. Liposomes 
are small artificial vesicles that form a globular shape that consists of 
an aquatic centre encapsulated with amphiphillic phospholipids and 
a cholesterol bilayer (Figure 5) [26]. Small unilamellar vesicles with a 
single lipid layer and a diameter of 25-50nm are best suited to active 
targeting due to their smaller size [27]. Liposomes can also increase 
their blood circulation time by incorporating the polymers PEG [28]. 
This allows them to be particularly effective as nanocarriers. Liposomes 
do have some potential issues if they are used as the material as 
it has been shown that there is variation between batch to batch 
manufacture, making the manufacture of a consistent nanocarrier 
difficult. Liposomes also suffer from low drug loading efficiency and a 
poor stability [10] which limits their usage as the ideal candidate for the 
material for actively targeted nanocarriers thorough BBB.
Micelles: There are two main types of micelle used as nanocarriers; 
Ligands Receptors
Ga, In, Fe Transferrin, Lactoferrin
Tl, K Na, K ATPase
Glucose, FDG Direct G-Protein Activation
Substance P Amino acid
a-methyltyrosine Estrogen
Estrogen, analogs, tamoxifen Sigma
Lodobenzamides Melanocyte
For more detailed information see reference [23].
Table 1: Selected receptors, and their corresponding ligands that are over ex-
pressed in tumour cells.
Vesicles
Micelles Polymers
Drug
Delivery
Carrier
Lipuid Crystals Nanocapsules
NanospheresNanotubes
Figure 4: Diagram showing several different materials that are currently un-
der consideration for nanodelivery to the brain, including Micelles, Vesicles, 
Polymers, Nanocapsules, Nanospheres, Nanotubes and Liquid crystals. Dia-
gram adapted from reference [24].
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polymeric micelles and phospholipid micelles. Both consist of a 
hydrophobic core surrounded by hydrophilic surface cells produced 
by amphiphillic molecules (Figure 6). This alters from a vesicle due to 
the single layer rather than the bilayer of amphiphillic molecules. This 
hydrophobic core makes micelles the perfect candidate for when you 
have poorly soluble drugs, as the drug can be internalized [29,30]. 
Polymeric micelles are made of polymers and there structure 
is closest to that of polymeric nanoparticles. Phospholipid micelles 
structure is closest to that of a vesicle. This means that they both suffer 
from similar strengths and weaknesses of those materials, but do have 
an advantage of a smaller size. 
Nanotubes: Carbon nanotubes (CNT) are essentially graphene 
sheets which are rolled up to produce perfect cylinders (Figure 7) 
[31]. Carbon nanotubes are chemically the most interesting of all the 
materials considered for the use as nanocarriers, as they give you a 
degree of control that is not possible with other materials as almost 
every carbon atom can be functionalised. This allows simple coupling 
chemistry then to be used to attach any molecule onto the CNT, 
allowing unlimited variations. This makes CNT the most flexible 
material that can be used as a nanocarrier.
Due to these limitless possibilities for functionalising the CNT a 
strong case can be made for this material being used for nanocarriers 
as it will able to be easily changed to be used for any function that it is 
needed.
There are two types of carbon nanotubes, single-walled (SWCNTs) 
and multi-walled (MWCNTs) [31]. SWCNT’s are best suited are best 
suited to being a nanocarrier due to their smaller size, and simpler 
coupling chemistry. All CNTs have a variable length from only 100-
200nm to a length of several microns [31]. This adds another factor 
of control that is possible with CNTs that is not possible with other 
materials. The diameter of the SWCNT is constantly extremely small 
as it is only a few nm [31]. Obviously the smaller the length of the CNT 
the more suitable it is to being a nanocarrier for the applications looked 
at in this review. 
The main drawback of carbon nanotubes that is relevant for use as 
nanocarriers is that in their non-functionalised form they are almost 
completely insoluble in all types of solvent [32]. This issue can be 
resolved by functionalised of the CNT; as it has been shown that with 
the addition of bioactive peptides on the side walls of the CNT become 
soluble [31,33]. This has only been tested in vivo (in the body) for a 
limited period, so more research must be conducted before this can be 
proven to be completely non-toxic. The addition of these groups can 
be made through the use of simple coupling chemistry. It is through 
this process that ligands for specific RMT pathways and image active 
molecules can be added to CNT or any nanocarrier. For this review 
CNT will be the focus of this section, although most of the examples 
shown can be used for other materials.
Simple coupling chemistry to generate biocompatible carbon 
nanotubes
To date, there are several methods reported to lead to covalently 
functionalised nanotubes suitable for biomedical applications. One 
of the most effective is the addition of 1,3-dipolar cycloaddition of 
azomethineylides [34]. The unfunctionalised CNTs must be in a 
Figure 5: Image of a vesicle.
Figure 6: Image of a micelle.
Figure 7: Image of a Carbon Nanotube.
R-NHCH2 COOH  +  R’-CHO
CNT,  DMF
R’
R
N
R
R’
N
Scheme 1: Addition of 1, 3-dipolar cycloaddition of azomethineylides to func-
tionalise a carbon nanotube. Adapted from reference [31].
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suspension of dimethylformide (DMF) and then a combination of 
N-substituted glycine and an aldehyde must be added. The reaction 
scheme is displayed in Scheme 1. The new functionalised groups 
produced by this reaction will be homogenously distributed all along 
CNT, allowing multiple different ligands to be added.
The effect of this functionalisation is that it allows the properties 
of the CNT to be altered by the addition of various ligands through 
different reactions. This can be achieved by using an accessible 
functionalised CNT: one such example is shown in Figure 8. This CNT 
can then be reacted to allow the addition of different ligands through 
various reactions, some examples are shown in Schemes (2-4). The 
percentage coverage of each ligand added can be controlled via the 
limitation of the amount of each ligand and reactant added.
There are many more standard coupling reactions that can be 
adapted for this purpose many of which highlighted in organic textbook 
[35]. There are issues that must be considered when choosing which 
coupling reactions to use, as a minute amount catalyst and reactants 
could reside in the CNT system as if these are toxic then could affect 
their efficiency and biocompatibility. This is an area that will have to be 
careful researched.
Appending drug-line molecules to Nanocarriers
In the design of nanocarriers a major consideration is the selection 
drugs that the nanocarriers are designed to deliver and the method via 
which they deliver those drugs. 
Method of attachment: The drugs can either be covalently linked to 
the external walls of the nanocarrier or they can become encapsulated 
into the structure. Drugs that are encapsulated can be either water or 
lipid soluble. There are many advantages of encapsulation as it prevents 
the drug from prematurely degrading or prematurely interacting with 
the biological environment [2]. The disadvantage of encapsulating is that 
the nanocarrier has to be homogenised for the drugs release meaning 
that drug release is difficult to control; although this does normally 
mean the drug is slowly released over time [2,36]. Encapsulating drugs 
could also suffer from a relatively poor drug loading as nanocarriers 
by definition have a high surface area to volume ratio. This means that 
a large quantity of the drug can be covalently linked onto the external 
walls of the nanocarrier. 
Drug-like molecules that are covalently linked onto the external 
walls of the nanocarrier can be only water soluble, because if a lipid sol-
uble drug was added then this would affect the nanocarriers’ properties 
[10]. The advantage of covalently linking drugs onto nanocarriers is the 
fact that this allows good drug loading and allows the best chance for 
an external trigger to be used for drug release [10]. This trigger could 
be a range of environmental conditions, or could possible come from 
an external source. The disadvantage of covalently linking is that it does 
allow the drugs to come in contact with the biological environment, but 
fortunately most drugs are inactive when linked. Drugs can be easily 
attached through simple coupling chemistry to the external walls, the 
method for encapsulation can be often much more complex. Overall it 
depends on the type of drug to determine which method is preferred; 
although for CNT external linkage could be the preferred method due 
to their small diameter making the issue of drug loading worse. 
Selected chemotherapeutics for brain tumour: There are 
thousands of drugs that could potentially benefit through the use of 
nanocarriers, including hundreds that are aimed towards tumorous 
cells. Chemotherapy drugs designed to rapidly reproducing cells, both 
cancerous and healthy, causing many side effects to the treatment. 
Chemotherapy drugs would massively benefit from active targeting of 
the target cells as it would prevent the main side effects that are caused 
by this treatment caused by the death of healthy cells. Example of a 
chemotherapy drug on the market is Taxol (Figure 9).
N
O
O
NH3
+Cl-
Figure 8: Image of the CNT with an easily functionalized group attached, 
i.e. PEG-NH3
+Cl-. Adapted from reference[31].
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Adapted from reference [31].
N
NH3
+CI-
o
o
N
N
O
O
O
O
O
O
N
O
O
O
O
O
HN
N
S
Cys-as-Lys(FlTC)
2)Free Peptide- SH 
1)
Scheme 3: Addition of Chemical ligand e.g. Fluorescent group  via –SH 
groups. Adapted from reference [31].
+ R - x
1)Pd(o)
2)Base
N
O
O
O
O
N
R’
Scheme 4: Via Heck reaction. Adapted from references.31 35
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In clinical tests at the moment are several drugs designed to target 
angiogenesis of the tumour cells. This method works by greatly cutting 
off the tumours blood supply, making the tumour reduce in size 
and allowing it to be surgically removed. Example of a clinical drug 
designed to target angiogenesis is Semaxanib (Figure 10)
Radiolabelled and Optically Tagged Targeted 
Nanoparticles for Brain Imaging
The vision of Nanotheranostics is that nanocarriers should be 
used as a diagnostic tool to diagnose diseases. It is doubtful that it is 
viable for actively targeted nanocarriers to be used for this purpose. 
This is because it would be a waste of resources to use a nanocarrier 
for a disease that hasn’t been confirmed to be in the body. If the person 
had already been diagnosed it is possible that it would be helpful to 
pinpoint the area where the disease is located, and this is the avenue 
this review will explore.
Molecular imaging
For this reason diagnostic imaging, in particular radiopharmaceu-
tical imaging is still an area that is crucial to the success of nanocarriers. 
This is a relatively new discipline that uses probes known as biomarkers 
to measure biological processes at a molecular level, allowing visualisa-
tion of events in a living system without causing any damage. This tech-
nique is useful in the diagnosis of cancer, as well as other neurological 
and cardiovascular diseases. There is a multitude of molecular imaging 
techniques, in this review we will only focus on a few of them with 
particular focus on the idea of multi-model imaging probes. The list of 
the most common of these molecular imaging techniques is in Table 2. 
Molecular imaging differs from traditional imaging techniques 
in that probes known as biomarkers are used to image particular 
targets. There are several biomarkers that correspond each the imaging 
technique; this is an area which will need research to find a suitable 
biomarker for the different applications of nanocarriers. Molecular 
imaging techniques are different from previous methods of imaging 
used in medicine. These imaged using the differences in objects or 
organisms that can be quantified such as density or water content.
Biomarkers are the key element in the operation of all molecular 
imaging techniques, and therefore these are going to have to be 
integrated into the design of the nanocarrier. These can be integrated 
onto a CNT nanocarrier using the coupling chemistry that has already 
been described. The attachment of this to the nanocarrier design can 
be seen in Figure 1` as they can be either encapsulated or covalently 
attached as discussed with reference with drug molecules. Table 2 
shows examples of suitable biomarkers for each molecular imaging 
technique.
Current biomarkers have a very low rate (1 in 10 000 chance) of 
reaching their therapeutic targets in vivo [24]. This means that the 
use of these biomarkers on the actively targeted nanocarrier could be 
beneficial to both as the active targeting will improve the rate of the 
biomarker reaching its therapeutic target.
Multimodality imaging
Molecular imaging techniques currently suffer from a severe 
limitation as no singular molecular imaging techniques has the detail 
required for imaging in vivo. This is because the techniques either lack 
the detail to be used for identifying specific targets or diseases, i.e. 
fluorescence, or are too detailed and can only scan a small area, i.e. PET. 
The level of detail presented by each technique is shown in Table 2. Due 
to these limitations the idea of multi-model imaging has emerged. This 
is where two imaging techniques are combined, to give both the detail 
required as well as the overview of the biodistribution of the target or 
disease. Many different example of multi-model imaging are currently 
in use, one of the most common is the combination of fluorescence and 
MRI [24] PET and SPECT could be very useful techniques to use due to 
their extremely high levels of detail. 
Applications of using multimodality imaging with nanoma-
terials
This utilisation of multi-model molecular imaging with the use of 
nanocarriers could potentially see many applications, both through the 
clinical tests and diagnostic potential. Although these applications are 
not a true diagnostic tool as the vision first implied, it does fulfil the 
diagnostic purpose in the sense of the examining the efficiency of the 
therapy.
Visualizing biodistribution in real time: The effectiveness of 
nanocarriers is dependent on their biodistribution, as it is imperative 
that they accumulate in the target site. The accumulation of nanocarriers 
in the incorrect site could lead to negative side effects. Multi-model 
imaging could facilitate the visualisation of biodistribution in real time, 
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Figure 9: Taxol.
N
H
N
H
O
Figure 10: Semaxanib.
Molecular Imaging Techniques Level of Detail provided
Molecular magnetic resonance imaging (MRI) Molecular
Optical Bioluminescence/Fluorescence Physiological 
Targeted Ultrasound Physiological 
Single Positron Emission Tomography (SPECT) Molecular (Detailed)
Positron Emission Tomography (PET)   Molecular (Detailed)
 Magnetoresistance probe (MR) Molecular
Information taken from reference [24,36].
Table 2: Table of Molecular Imaging techniques, relative level of detail and ex-
ample biomarkers.
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as all the techniques are non-invasive. This application can be achieved 
through the use of almost any radionuclides and molecular imaging 
techniques. This allows a great range of options for the nanocarriers 
design. 
An example of this in action is displayed by Figure 12 A as it displays 
the biodistribution of indium-111-labelled PEGylated liposomes. 
These images were taken 72 hours after injection by SPECT imaging 
[38]. This shows how the liposomes have been distributed around the 
body and collects in different areas. The tumour that was targeted was 
located in the tongue (Tu), and this is where some of the nanocarriers 
did collect [38]. The other places revealed that the nanocarrier collected 
was in the patient’s cardiac pool (CP), liver (L) and Spleen (Spl) [38].
Monitoring drug distribution at the target site: Investigation into 
the overall levels of drug accumulation at the target site is important, 
but equally important is the ability to visualize and analyse drug 
distribution at the target site. This allows medical chemists to ensure 
that there is an equal biodistribution of the nanocarrier throughout the 
tumour. It is through this method that it was discovered that passively 
targeted nanocarriers tend to collect in one area of the tumour instead 
of being equally distributed as mentioned in the introduction. An 
example of this close imaging is displayed in Figure 12 B-D which 
shows by the distribution of Indium-111-labelled PEGylated liposomes 
in a tumour in the tongue [38].
Visualizing drug release: The majority of drugs that are attached 
to nanocarriers are inactive when they are covalently linked [36]. 
Therefore it is vital to ensure that the drugs are being released 
correctly. Nanocarriers that have imaging capabilities could allow this 
visualisation to take place. This is important as it is difficult to ensure 
that the drug have been released in vivo, as the nanocarrier often needs 
to be homogenised for the drug to be released making imaging difficult 
once this has occurred [36]. For this technique to function two different 
imaging agents would be needed, one for when the system is still intact, 
and one that only produces a signal upon the drugs release. The first 
would be a form of radionuclide that is attached to or encapsulated 
in the nanocarrier to allow the monitoring of the nanocarrier with 
the above applications. As with those applications a wide range of 
radionuclides can be used. The second would be an agent that is inactive 
when attached to or encapsulated in the nanocarrier, but is active when 
it is able to interact with the surrounding biological environment. 
Examples that have been tried and tested for this use are MR contrast 
agents (gadolinium and manganese based) as there activation depends 
on their interaction with surrounding water molecules [39-41].
Facilitating triggered drug release: The applications that have been 
reviewed so far have been purely based on measuring and reviewing the 
efficiency of the nanocarriers and the drugs that are attached. Imaging 
techniques could be used to enhance their effectiveness instead of just 
being measure. Imaging techniques could allow the optimum release of 
the drug into the tumorous cells. This could be done if the activation of 
the drugs release could be activated using an external source. Thereby 
the imaging techniques could be used to determine the optimum point 
to release the drug, and then the external source could be used to 
release the drug. This process could accomplish release of the drug in 
specific areas of the target site to ensure that only the sites that are in 
optimum conditions are released. High-intensity focused ultrasound 
would be an example of a possible external source, as radiofrequency 
waves could be used for this purpose [36]. 
Predicting drug responses: Use of multi-model imaging techniques 
allow additional information to be obtained during the clinical phases 
of the nanocarrier development. This could be with specific regard 
to the drugs or nanocarrier that was used. This information allows 
predictions to be made on the potential effectiveness. This would 
allow modifications to be made or the investment to be stopped into 
this specific combination of a drug and a nanocarrier. This could 
potentially save researchers valuable time and money. This process is 
referred to as self-regulation; as potential problems can be spotted early 
Receptor
on target
cell, i.e.
tumour cell
Targeting
group
Biocompatible /
florescent coating
Nanocarrier
encapsulated
radionuclides
Figure 11: This diagram displays the image of a nanocarrier with a ligand 
attached and a radionuclide-based imaging agent encapsulated. These allow 
molecular imaging to take place, and could lead to interesting applications for 
whole body imaging.
Tu
CP
Spl
L
C
B
A
D
Figure 12: A, B, C, D as it displays the biodistribution of indium-111-labelled 
PEGylated liposomes. These images were taken 72 hours after injection 
by SPECT imaging. A shows the overall biodistribution of the nanocarriers, 
which was targeted at the tumour located in the tongue (Tu). The other 
places revealed that the nanocarrier collected was in the image was the pa-
tient’s cardiac pool (CP), liver (L) and Spleen (Spl). B, C, D shows a detailed 
image of the distribution of Indium-111-labelled PEGylated liposomes in a 
tumour in the tongue. Image adapted from Reference [37].
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and corrections can be made. This can be for a wide number of reasons 
such as effectiveness, toxicity and side effects.
Evaluating drug efficacy longitudinally: These applications allow 
the nanocarrier distribution at the target site to be monitored and 
altered. This allows extensive studies to be completed to evaluate the 
effectiveness of targeted drug delivery and to discover the route through 
the body the nanocarrier took to reach the target site. This will allow 
medical chemists to better understand and better predict why certain 
treatments are effective, and why others are not. This is only possible in 
the cases when all the techniques used (for diagnosis and therapy) are 
non-invasive, and so can be part of a long term investigation. 
Conclusion
Recently, new strategies to overcome the BBB in order to treat 
disorders of the CNS (highlighting the role that nanotechnology can 
play in mediating the transfer of small molecules as well as therapeutic 
antibodies through this barrier formed by endothelial cells, astrocyte 
and pericytes) have been developed [42] and reviewed [43]. 
The ability to combine the diagnosis of disease with therapy using 
very low doses of the overall drug given to a patient constitutes the 
original vision of nanotheranostics. Nanomedicines design will lead 
to improved drug accumulation to the tumour / site of action and a 
controlled / limited effect on the surrounding healthy tissue. The 
viability of this vision with regard to diagnosis of disease remains a 
matter of intense investigations [44,45].
This is especially true if diagnosis is taken in its strictest sense; 
i.e. the localisation and identification of diseased cells in the body. If 
diagnosis is interpreting in its broader sense, i.e. the longitudinal study 
of the therapeutic effects of a nanocarrier drug complex, then there 
is a great potential as a research tool in this area. This application of 
imaging is extremely beneficial to both drug design, in both clinical 
and pre-clinical tests, and allow early identification of otherwise 
unexpected side effects. The combination of this technology with the 
new emerging field of precise and active targeting will allow for the 
development of the nanocarrier drug complex to be efficient and have 
excellent self-regulation.
Candidates for nanocarriers that can precisely and actively target 
are only starting to emerge and still have many issues that must be 
overcome for it to function. The main bottleneck to the design of these 
nanocarriers will be their ability to cross the BBB. 
Encapsulation and targeted delivery will make any drug it carries 
more effective, reducing the likelihood of side effects, i.e. damage 
to healthy cells, increased efficiency of the active drug in target site 
intact and the possibility for externally-triggered release on demand, 
monitored via imaging of drug delivery. The potential benefits of the 
design of nanocarriers including those as described above are clear and 
the risks are similarly under intense public and regulatory scrutiny. 
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